These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 37313406)

  • 1. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
    Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
    Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
    BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: Systematic review and meta-analysis of real-world evidence.
    Xie W; Xiao S; Li X; Huang J; Li G; Zhang Z
    Eur J Intern Med; 2023 Sep; 115():88-95. PubMed ID: 37263805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study.
    Ji MS; Wu R; Feng Z; Wang YD; Wang Y; Zhang L; Sun XF; Chen XM; He KL; Cai GY
    Sci Rep; 2022 Nov; 12(1):18752. PubMed ID: 36335144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitor-associated acute kidney injury in patients with cancer: a systematic review and meta-analysis of risk factors.
    Yan H; Tang M; Zhu W; Yang Y
    Clin Exp Nephrol; 2023 Jul; 27(7):603-612. PubMed ID: 37014535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Proton Pump Inhibitor Use and Immune Checkpoint Inhibitor-Mediated Acute Kidney Injury: A Meta-Analysis and a Review of Related Outcomes.
    Mohan A; Krisanapan P; Tangpanithandee S; Thongprayoon C; Kanduri SR; Cheungpasitporn W; Herrmann SM
    Am J Nephrol; 2024; 55(4):439-449. PubMed ID: 38471492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis.
    Whitlock R; Leon SJ; Manacsa H; Askin N; Rigatto C; Fatoba ST; Farag YMK; Tangri N
    Nephrol Dial Transplant; 2023 Oct; 38(11):2503-2516. PubMed ID: 37309038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-Converting Enzyme Inhibitor/Receptor Blocker, Diuretic, or Nonsteroidal Anti-inflammatory Drug Use After Major Surgery and Acute Kidney Injury: A Case-Control Study.
    Roberts DJ; Smith SA; Tan Z; Dixon E; Datta I; Devrome A; Hemmelgarn BR; Tonelli M; Pannu N; James MT
    J Surg Res; 2021 Jul; 263():34-43. PubMed ID: 33631376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study.
    Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study.
    Gérard AO; Barbosa S; Parassol N; Andreani M; Merino D; Cremoni M; Laurain A; Pinel S; Bourneau-Martin D; Rocher F; Esnault VLM; Borchiellini D; Sicard A; Drici MD;
    Clin Kidney J; 2022 Oct; 15(10):1881-1887. PubMed ID: 36158153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
    Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
    Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
    [No Abstract]   [Full Text] [Related]  

  • 12. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
    Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
    Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors.
    Liu F; Wang Z; Li X; Zhang Z; Yang Y; Chen J; Chen D; Wu L; Liu X; Han S; Wang F; Wahafu W; Gao Y; Ren S; Xing N; Cai G; Chen X
    Cancer Commun (Lond); 2023 Feb; 43(2):214-224. PubMed ID: 36528491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study.
    Liu K; Qin Z; Ge Y; Bian A; Xu X; Wu B; Xing C; Mao H
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5061-5070. PubMed ID: 36326913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute kidney injury in cancer patients receiving anti-vascular endothelial growth factor monoclonal antibody vs. immune checkpoint inhibitors: a retrospective real-world study.
    Zhu J; Ding X; Zhang J; Chen B; You X; Chen X; Chen T
    BMC Cancer; 2024 Jun; 24(1):756. PubMed ID: 38914959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
    Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review.
    Li H; Zhang L; Yang F; Zhao R; Li X; Li H
    Front Immunol; 2023; 14():1218386. PubMed ID: 37841249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug discontinuation before contrast procedures and the effect on acute kidney injury and other clinical outcomes: a systematic review protocol.
    Hiremath S; Kayibanda JF; Chow BJW; Fergusson D; Knoll GA; Shabana W; Lahey B; McBride O; Davis A; Akbari A
    Syst Rev; 2018 Feb; 7(1):34. PubMed ID: 29467030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors.
    Guven DC; Ozbek DA; Sahin TK; Kavgaci G; Aksun MS; Erul E; Yildirim HC; Chalabiyev E; Cebroyilov C; Yildirim T; Dizdar O; Aksoy S; Yalcin S; Kilickap S; Erman M; Arici M
    Anticancer Drugs; 2023 Jul; 34(6):783-790. PubMed ID: 36729111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Shen J; Hou H; Liang B; Guo X; Chen L; Yang Y; Wang Y
    Front Immunol; 2023; 14():1155104. PubMed ID: 37153578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.